View Filing Data

Print Document View Excel Document

Document and Entity Information Document - shares	9 Months Ended
Document and Entity Information Document - shares	Sep. 30, 2014	Oct. 30, 2014
Document Information [Line Items]
Entity Registrant Name	NeoStem, Inc.
Entity Central Index Key	0000320017
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		35,738,358

Consolidated Balance Sheets - USD ($)	Sep. 30, 2014	Dec. 31, 2013
Current Assets
Cash and cash equivalents	$ 32,141,286	$ 46,133,759
Marketable securities	665,112	0
Accounts receivable, net of allowance for doubtful accounts of $386,066 and $391,829 at September 30, 2014 and December 31, 2013, respectively	2,088,888	1,860,835
Inventory	2,142,302	1,270,223
Prepaid expenses and other current assets	4,376,353	1,561,933
Total current assets	41,413,941	50,826,750
Property, plant and equipment, net	15,686,609	12,844,216
Goodwill	25,209,336	11,117,770
Intangible assets, net	47,711,709	13,875,617
Other assets	1,317,082	1,151,729
Assets, Total	131,338,677	89,816,082
Current Liabilities
Accounts payable	4,400,437	3,354,908
Accrued liabilities	2,818,623	4,018,026
Notes payable	995,576	381,097
Mortgages payable	0	213,112
Derivative liabilities	0	23,175
Unearned revenues	3,639,979	1,816,601
Total current liabilities	11,854,615	9,806,919
Long-term Liabilities
Deferred income taxes	18,422,575	4,379,226
Notes payable	956,515	531,164
Mortgages payable	0	3,023,609
Long-term Debt, Excluding Current Maturities	15,000,000	0
Acquisition-related contingent consideration	22,430,000	9,450,000
Other long-term liabilities	616,000	598,729
Liabilities	69,279,705	27,789,647
Commitments and Contingencies
Stockholders' Equity
Preferred stock, authorized, 20,000,000 shares; Series B convertible redeemable preferred stock liquidation value, 0.01 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at September 30, 2014 and December 31, 2013	100	100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 35,485,523 and 27,196,537 shares, at September 30, 2014 and December 31, 2013, respectively	35,486	27,197
Additional paid-in capital	343,308,264	299,594,525
Treasury stock, at cost	(705,742)	(705,742)
Accumulated deficit	(279,634,948)	(236,373,605)
Accumulated other comprehensive income	112	0
Total NeoStem, Inc. stockholders' equity	63,003,272	62,542,475
Noncontrolling interests	(944,300)	(516,040)
Total equity	62,058,972	62,026,435
Liabilities and Equity, Total	$ 131,338,677	$ 89,816,082

Consolidated Balance Sheets (Parentheticals) - USD ($)	Sep. 30, 2014	Dec. 31, 2013
Preferred Stock, Shares Outstanding	10,000	10,000
Common Stock, Par Value	$ 0.001	$ 0.001
Accounts receivable trade, net of allowance for doubtful accounts	$ 2,088,888	$ 1,860,835
Preferred Stock, authorized	20,000,000	20,000,000
Common stock, outstanding	35,485,523	27,196,537
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares, Issued	35,485,523	27,196,537
Preferred stock, shares designated	825,000	825,000
Preferred stock, issued	10,000	10,000
Preferred stock, Series B convertible redeemable preferred stock liquidation value, share of common stock	0.01	0.01
Preferred stock, par value	$ 0.01	$ 0.01

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
Consolidated Statements of Operations - USD ($)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues	$ 4,117,783	$ 3,706,918	$ 12,662,290	$ 10,590,237
Cost of revenues	4,012,369	2,975,935	11,515,168	9,603,048
Research and development	8,469,623	4,486,389	19,024,728	11,619,843
Selling, general, and administrative	7,894,291	5,557,425	24,310,324	15,681,731
Total operating costs and expenses	20,376,283	13,019,749	54,850,220	36,904,622
Operating loss	(16,258,500)	(9,312,831)	(42,187,930)	(26,314,385)
Other income (expense):
Other income (expense), net	(687,280)	179,605	(1,062,568)	248,161
Interest expense	(183,477)	(98,618)	(383,539)	(208,023)
Nonoperating Income (Expense), Total	(870,757)	80,987	(1,446,107)	40,138
Loss before provision for income taxes and noncontrolling interests	(17,129,257)	(9,231,844)	(43,634,037)	(26,274,247)
Provision for income taxes	47,387	44,757	142,183	492,325
Net loss	(17,176,644)	(9,276,601)	(43,776,220)	(26,766,572)
Less - loss attributable to noncontrolling interests	(202,375)	(205,844)	(514,877)	(319,880)
Net loss attributable to NeoStem, Inc. common stockholders	$ (16,974,269)	$ (9,070,757)	$ (43,261,343)	$ (26,446,692)
Basic and diluted loss per share attributable to NeoStem, Inc. common stockholders	$ (0.48)	$ (0.45)	$ (1.37)	$ (1.43)
Weighted average common shares outstanding	35,053,218	20,203,934	31,663,221	18,482,413

Consolidated Statements of Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
Consolidated Statements of Comprehensive Loss - USD ($)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Net loss	$ (17,176,644)	$ (9,276,601)	$ (43,776,220)	$ (26,766,572)
Available for sale securities - net unrealized (loss) gain	(886)	0	112	0
Total other comprehensive income	(886)	0	112	0
Comprehensive loss	(17,177,530)	(9,276,601)	(43,776,108)	(26,766,572)
Comprehensive loss attributable to noncontrolling interests	(202,375)	(205,844)	(514,877)	(319,880)
Comprehensive net loss attributable to NeoStem, Inc. common stockholders	$ (16,975,155)	$ (9,070,757)	$ (43,261,231)	$ (26,446,692)

Consolidated Statements of Equity - USD ($)	Total	Total NeoStem, Inc. Shareholders' Equity [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Noncontrolling Interest [Member]
Beginning Balance (shares) at Dec. 31, 2012			10,000	16,375,365
Beginning Balance at Dec. 31, 2012	$ 32,820,159	$ 33,177,129	$ 100	$ 16,375	$ 231,218,615	$ 0	$ (197,392,361)	$ (665,600)	$ (356,970)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(26,766,572)	(26,446,692)					(26,446,692)		(319,880)
Share-based compensation (in shares)				451,666
Share-based compensation	5,412,451	5,412,451		$ 452	5,441,166
Stock Granted, Value, Share-based Compensation, Forfeited								(29,167)
Stock Issued During Period, Shares, New Issues				3,949,255
Net proceeds from issuance of common stock	21,517,422	21,517,422		$ 3,949	21,513,473
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				16,369
Proceeds from exercise of options	86,658	86,658		$ 16	86,642
Proceeds from warrant exercise (in shares)				401,215
Stock Issued During Period, Value, Warrant Exercises	2,126,291	2,126,291		$ 402	2,125,889
Warrant Inducements	(62,014)	(62,014)			(62,014)
Change in Ownership in Subsidiary	0	(111,680)			(111,680)				111,680
Ending Balance at Sep. 30, 2013	35,134,395	35,699,565	$ 100	$ 21,194	260,212,091	0	(223,839,053)	(694,767)	(565,170)
Ending Balance (shares) at Sep. 30, 2013			10,000	21,193,870
Beginning Balance (shares) at Dec. 31, 2013			10,000	27,196,537
Beginning Balance at Dec. 31, 2013	62,026,435	62,542,475	$ 100	$ 27,197	299,594,525	0	(236,373,605)	(705,742)	(516,040)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(43,776,220)	(43,261,343)					(43,261,343)		(514,877)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	112	112				112
Share-based compensation (in shares)				727,158
Share-based compensation	8,941,452	8,941,452		$ 727	8,940,725
Stock Issued During Period, Shares, New Issues				1,850,081
Net proceeds from issuance of common stock	11,275,109	11,275,109		$ 1,850	11,273,259
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				48,987
Proceeds from exercise of options	271,008	271,008		$ 49	270,959
Proceeds from warrant exercise (in shares)				333,250
Stock Issued During Period, Value, Warrant Exercises	1,720,725	1,720,725		$ 333	1,720,392
Stock Issued During Period, Shares, Acquisitions				5,329,510
Stock Issued During Period, Value, Acquisitions	21,600,351	21,600,351		$ 5,330	21,595,021
Change in Ownership in Subsidiary	0	(86,617)			(86,617)				86,617
Ending Balance at Sep. 30, 2014	$ 62,058,972	$ 63,003,272	$ 100	$ 35,486	$ 343,308,264	$ 112	$ (279,634,948)	$ (705,742)	$ (944,300)
Ending Balance (shares) at Sep. 30, 2014			10,000	35,485,523

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:
Net loss	$ (43,776,220)	$ (26,766,572)
Adjustments to reconcile net loss to net cash used in operating activities:
Equity-based compensation expense	8,941,452	5,412,451
Depreciation and amortization	1,578,334	1,197,801
Changes in fair value of derivative liability	(23,175)	12,952
Change in acquisition-related contingent consideration	1,090,000	0
Bad debt recovery	(5,763)	(232,531)
Deferred income taxes	142,183	492,325
Accretion Expense	7,329	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(2,795,249)	(663,543)
Accounts receivable	(177,162)	(108,363)
Inventory	(872,079)	583,659
Unearned revenues	1,823,379	(446,399)
Other assets	559,470	421
Accounts payable, accrued liabilities and other liabilities	(2,483,740)	780,100
Net cash used in operating activities	(35,991,241)	(19,737,699)
Cash flows from investing activities:
Net cash received in acquisitions	50,894	0
Purchase of marketable securities	(920,329)	0
Proceeds from Sale and Maturity of Marketable Securities	248,000	0
Acquisition of property, plant and equipment	(2,925,918)	(948,644)
Net cash used in investing activities	(3,547,353)	(948,644)
Cash flows from financing activities:
Proceeds from exercise of options	271,008	86,658
Proceeds from exercise of warrants	1,720,725	2,126,291
Net proceeds from issuance of common stock	11,275,109	21,517,422
Proceeds from Issuance of Long-term Debt	14,476,170	0
Repayment of mortgage loan	(3,236,721)	(150,294)
Proceeds from notes payable	1,777,163	709,741
Repayment of notes payable	(737,333)	(332,713)
Payment for warrant inducement	0	(62,014)
Net cash provided by financing activities	25,546,121	23,895,091
Net (decrease) increase in cash and cash equivalents	(13,992,473)	3,208,748
Cash and cash equivalents at beginning of period	46,133,759	13,737,452
Cash and cash equivalents at beginning of period	32,141,286	16,946,200
Cash paid during the period for:
Interest	359,300	202,800
Taxes	0	0
Common stock and contingent consideration issued in merger	$ 33,490,351	$ 0

The Business

9 Months Ended

Sep. 30, 2014

The Business [Abstract]

Nature of Operations [Text Block]

The Business

Overview

NeoStem, Inc. (“we,” “NeoStem” or the “Company”) is a leader in the emerging cellular therapy industry. We are pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease. We have multiple cell therapy platforms that work to address the pathology of disease using a person's own cells to amplify the body's natural repair mechanisms including enhancing the destruction of cancer initiating cells, repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that cell therapy will play a large role in changing the natural history of diseases as more breakthrough therapies are developed, ultimately lessening the overall burden of disease on patients and their families as well as the economic burden that these diseases impose upon modern society.

Our business includes the development of novel proprietary cell therapy products, as well as a revenue-generating contract development and manufacturing service business that we leverage for the development of our therapeutics while providing services to other companies in the cell therapy industry. The combination of our own therapeutic development business and a revenue-generating service provider business provides the Company with unique capabilities for cost effective in-house product development and immediate revenue and future cash flow to help underwrite our internal development programs. This business model enables the Company to be opportunistic in growing its pipeline as evidenced by the Company's acquisition in May 2014 of California Stem Cell, Inc. ("CSC"), a cell biotechnology company located in Irvine, California.

Since our acquisition of the CSC business, we are developing cellular immunotherapies for cancer, an area we view to be one of the most promising sub-sectors in biotechnology. Our lead product candidate in our immunotherapy pipeline is NBS20, also referred to as DC/TC (dendritic cell/tumor cell), and is targeting malignant melanoma initiating cells. This immunotherapy designed to treat Stage IV or recurrent Stage III metastatic melanoma, which has been granted fast track and orphan designation by the Food and Drug Administration ("FDA"), also has a Phase 3 protocol that is the subject of a Special Protocol Assessment ("SPA"). The SPA indicates that the FDA is in agreement with the design, clinical endpoints, and planned clinical analyses of the Phase 3 trial that could serve as the basis for a Biologics License Application ("BLA") that would be filed with the FDA requesting marketing approval of this therapeutic candidate. This protocol calls for enrolling 250 evaluable patients and in the fourth quarter of 2014 we began activating clinical sites. Patient enrollment is expected to begin in the first quarter of 2015. We are evaluating other clinical indications into which we may advance this program, including liver, ovarian and lung cancers.

We are also currently developing therapies to address ischemia utilizing CD34 cells. Ischemia occurs when the supply of oxygenated blood in the body is restricted. We seek to improve oxygen delivery to tissues through the development and formation of new blood vessels. NBS10, also referred to as AMR-001, is our most clinically advanced product candidate in our ischemic repair program and is being developed to treat damaged heart muscle following an acute myocardial infarction (heart attack) ("AMI"). In December 2013, the Company completed enrollment in its 160 patient PreSERVE AMI study. PreSERVE AMI is a randomized, double-blinded, placebo-controlled Phase 2 clinical trial testing NBS10, an autologous (donor and recipient are the same) adult stem cell product for the treatment of patients with left ventricular dysfunction following acute ST segment elevation myocardial infarction (STEMI). The Company anticipates releasing data from the PreSERVE AMI study on November 17, 2014 at the American Heart Association's Scientific Sessions and will release sooner if available. If approved by the FDA and/or other worldwide regulatory agencies following successful completion of further trials, NBS10 would address a significant medical need for which there is currently no effective treatment, potentially improving longevity and quality of life for those suffering a STEMI, and positioning the Company to capture a meaningful share of this worldwide market. We are evaluating other clinical indications into which we may advance this program.

Another platform technology we are developing utilizes T Regulatory Cells ("Tregs") to treat diseases caused by imbalances in an individual's immune system. Collaborating with the University of California, San Francisco, we are utilizing the technology platform of our majority-owned subsidiary, Athelos Corporation ("Athelos"), to restore immune balance by enhancing Treg cell number and function. Tregs are a natural part of the human immune system and regulate the activity of T effector cells, the cells that are responsible for protecting the body from viruses and other foreign antigens. When Tregs function properly, only harmful foreign materials are attacked by T effector cells. In autoimmune disease it is thought that deficient Treg activity permits the T effector cells to attack the body's own tissues, while in allergic diseases, like asthma, it is thought that the immune system overreacts to harmless foreign substances. We plan to initiate in the first half of 2015, subject to review and approval of the protocol by the appropriate regulatory authorities, a Phase 2 study of NBS03D, a Treg based therapeutic, in the treatment of type 1 diabetes. We plan to initiate in the fourth quarter of 2015, subject to review and approval of the protocol by the appropriate regulatory authorities, a Phase 1 study in Canada of NBS03A, a Treg based therapeutic, in support of our steroid resistant asthma development program.

Regenerative medicine holds the promise of improving clinical outcomes and reducing overall healthcare costs. We have two pre-clinical assets including our VSEL^TM (Very Small Embryonic Like) Technology regenerative medicine platform and our dermatological program. We are working on a Department of Defense funded study of VSELs^TM for the treatment of chronic wounds and exploring macular degeneration with the Schepens Eye Research Institute, an affiliate of Harvard Medical School. As part of our dermatological program, we are pursuing partnering arrangements to fund further development and distribution.

Progenitor Cell Therapy, LLC ("PCT") is a revenue generating contract manufacturing and development organization in the cellular therapy industry. This wholly owned subsidiary, which we acquired in 2011, is recognized around the world as an industry leader in providing high quality manufacturing capabilities, support and innovative engineering solutions to developers of cell-based therapies, enabling improved efficiencies and profitability, while reducing the capital investment required for these development activities. Since its inception more than 15 years ago, PCT has provided pre-clinical and clinical current Good Manufacturing Practice (“cGMP”) development and manufacturing services to more than 100 clients. PCT has experience in advancing regenerative medicine product candidates from product inception through rigorous quality standards all the way through to human testing, BLA filing and FDA product approval. PCT's core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, manufacturing development through its engineering and innovation services, analytical development, cell and tissue processing, regulatory support, storage, distribution and delivery, and consulting services. PCT has three cGMP compliant facilities in Allendale, NJ, Mountain View, CA and Irvine, CA. PCT's state-of-the art cell therapy research, development, and manufacturing facilities serve the cell therapy community with integrated and regulatory compliant distribution capabilities. The Company is pursuing commercial expansion of our manufacturing operations both in the U.S. and internationally.

Strategic acquisitions have been the cornerstone of NeoStem’s growth and have been selected in order to provide value to stockholders by taking advantage of the infrastructure we have created which includes strong development, regulatory and manufacturing expertise. By adding NBS20, our DC/TC product candidate and a late stage novel proprietary cancer cell therapy into our pipeline, we look to further advance towards our goal of delivering transformative cell based therapies to the market to help patients suffering from life-threatening medical conditions. Coupled with our strong manufacturing capability, we believe the stage is set for us to realize meaningful clinical development and manufacturing efficiencies, further positioning NeoStem to lead the cell therapy industry.

Basis of Presentation

The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of September 30, 2014 and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2013 and 2012 included in our Annual Report on Form 10-K for the year ended December 31, 2013. Operating results for the nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates.

Reclassifications

Certain reclassifications have been made to the Consolidated Financial Statements and Notes to the Consolidated Financial Statements for the three and nine months ended September 30, 2013 to conform to the presentation for the three and nine months ended September 30, 2014.

Principles of Consolidation

The Consolidated Financial Statements include the accounts of NeoStem, Inc. and its wholly owned and partially owned subsidiaries and affiliates as listed below.



Entity	Percentage of Ownership	Location
NeoStem, Inc.	Parent Company	United States of America
NeoStem Therapies, Inc.	100%	United States of America
Stem Cell Technologies, Inc.	100%	United States of America
Amorcyte, LLC	100%	United States of America
Progenitor Cell Therapy, LLC (PCT)	100%	United States of America
NeoStem Family Storage, LLC	100%	United States of America
Athelos Corporation (1)	90%	United States of America
PCT Allendale, LLC	100%	United States of America
NeoStem Oncology, LLC (2)	100%	United States of America

(1) Pursuant to the Stock Purchase Agreement signed in March 2011, our initial ownership in Athelos was 80.1%, and Becton Dickinson's ("BD") initial minority ownership was 19.9%. Per the Agreement, BD will be diluted based on new investment in Athelos by us (subject to certain anti-dilution provisions). As of September 30, 2014, BD's ownership interest in Athelos was decreased to 10.0%, and our ownership increased to 90.0% As a result in the change in ownership, approximately $0.1 million was transferred from additional paid in capital to non-controlling interests.

(2) On May 8, 2014, NeoStem acquired CSC, now known as NeoStem Oncology, LLC (see Note 3, Acquisition). Accordingly, the operating results of NeoStem Oncology, LLC prior to May 8, 2014 are not included in the Company's consolidated operations and cash flows.

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2014

Summary of Significant Accounting Policies [Abstract]

Summary of Significant Accounting Policies [Text Block]

Summary of Significant Accounting Policies

In addition to the policies below, our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2013. There were no changes to our significant accounting policies during the nine months ended September 30, 2014.

Cash and Cash Equivalents

Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.

Marketable Securities

The Company determines the appropriate classification of our marketable securities at the time of purchase and reevaluate such designation at each balance sheet date. All of our marketable securities are considered as available-for-sale and carried at estimated fair values and reported in either cash equivalents or marketable securities. Unrealized gains and losses on available-for-sale securities are excluded from net income and reported in accumulated other comprehensive income (loss) as a separate component of stockholders' equity. Other income (expense), net, includes interest, dividends, amortization of purchase premiums and discounts, realized gains and losses on sales of securities and other-than-temporary declines in the fair value of securities, if any. The cost of securities sold is based on the specific identification method. We regularly review all of our investments for other-than-temporary declines in fair value. Our review includes the consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether we have the intent to sell the securities and whether it is more likely than not that we will be required to sell the securities before the recovery of their amortized cost basis. When we determine that the decline in fair value of an investment is below our accounting basis and this decline is other-than-temporary, we reduce the carrying value of the security we hold and record a loss for the amount of such decline.

Accounts Receivable

Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. The Company applies judgment in connection with establishing the allowance for doubtful accounts. Specifically, the Company analyzes the aging of accounts receivable balances, historical bad debts, customer concentration and credit-worthiness, current economic trends and changes in the Company’s customer payment terms. Significant changes in customer concentrations or payment terms, deterioration of customer credit-worthiness or weakening economic trends could have a significant impact on the collectability of the receivables and the Company’s operating results. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Management regularly reviews the aging of receivables and changes in payment trends by its customers, and records a reserve when it believes collection of amounts due are at risk.

Inventories

The Company, through its PCT subsidiary, regularly enters into contracts with clients for services that have multiple stages and are dependent on one another to complete the contract and recognize revenue. The Company's inventory primarily represents work in process for costs incurred on such projects at PCT that have not been completed. The Company reviews these projects periodically to determine that the value of each project is stated at the lower of cost or market.

Goodwill and Other Intangible Assets

Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. The Company’s intangible assets with an indefinite life are related to in process research and development ("IPR&D") programs acquired in the Amorcyte and CSC acquisitions, as the Company expects future research and development on these programs to provide the Company with substantial benefit for a period that extends beyond the foreseeable horizon. Intangible assets with indefinite useful lives are measured at their respective fair values as of the acquisition date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Intangible assets related to IPR&D projects are considered to be indefinite-lived until the completion or abandonment of the associated R&D efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time.

The Company reviews goodwill and indefinite-lived intangible assets at least annually for possible impairment. Goodwill and indefinite-lived intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. The Company tests its goodwill and indefinite-lived intangible assets each year on December 31. The Company reviews the carrying value of goodwill and indefinite-lived intangible assets utilizing a discounted cash flow model, and, where appropriate, a market value approach is also utilized to supplement the discounted cash flow model. The Company makes assumptions regarding estimated future cash flows, discount rates, long-term growth rates and market values to determine each reporting unit’s estimated fair value.

Amortized intangible assets consist of customer lists, manufacturing technology, tradenames, patents and rights. These intangible assets are amortized on a straight line basis over their respective useful lives.

Revenue Recognition

Clinical Services: The Company recognizes revenue for its (i) process development and (ii) clinical manufacturing services based on the terms of individual contracts.

Revenues associated with process development services generally contain multiple stages that do not have stand-alone values and are dependent upon one another, and are recognized as revenue on a completed contract basis. We recognize revenues when all of the following conditions are met:


•	persuasive evidence of an arrangement exists;


•	delivery has occurred or the services have been rendered;


•	the fee is fixed or determinable; and


•	collectability is probable.

The Company considers signed contracts as evidence of an arrangement. The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the payment terms are subject to refund or adjustment. The Company assesses cash collectability based on a number of factors, including past collection history with the client and the client's creditworthiness. If the Company determines that collectability is not reasonably assured, it defers revenue recognition until collectability becomes reasonably assured, which is generally upon receipt of the cash. The Company's arrangements are generally non-cancellable, though clients typically have the right to terminate their agreement for cause if the Company materially fails to perform.

Clinical manufacturing services are generally distinct arrangements whereby the Company is paid for time and materials or for fixed monthly amounts. Revenue is recognized when efforts are expended or contractual terms have been met.

Some client agreements include multiple elements, comprised of process development and clinical manufacturing services. The Company believes that process development and clinical manufacturing services each have stand-alone value because these services can be provided separately by other companies. In accordance with ASC Update No. 2009-13, “Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements,” the Company (1) separates deliverables into separate units of accounting when deliverables are sold in a bundled arrangement and (2) allocates the arrangement's consideration to each unit in the arrangement based on its relative selling price.

Clinical Services Reimbursements: The Company separately charges the customers for the expenses associated with certain consumable resources (reimbursable expenses) that are specified in each clinical services contract. On a monthly basis, the Company bills customers for reimbursable expenses and immediately recognizes these billings as revenue, as the revenue is deemed earned as reimbursable expenses are incurred. For the three months ended September 30, 2014 and 2013, clinical services reimbursements were $1.0 million and $0.6 million, respectively. For the nine months ended September 30, 2014 and 2013, clinical services reimbursements were $2.8 million and $1.4 million, respectively.

Processing and Storage Services: The Company recognizes revenue related to the collection and cryopreservation of cord blood and autologous adult stem cells when the cryopreservation process is completed which is approximately twenty-four hours after cells have been collected. Revenue related to advance payments of storage fees is recognized ratably over the period covered by the advance payments.

New Accounting Pronouncement

In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)." The new revenue recognition standard provides a five-step analysis to determine when and how revenue is recognized. The standard requires that a company recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This ASU is effective for annual periods beginning after December 15, 2016 and will be applied retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is currently evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements.

In August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements - Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements - Liquidation Basis of Accounting. Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the provisions in this ASU should be followed to determine whether to disclose information about the relevant conditions and events. The ASU in this Update is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company is currently evaluating the adoption of this ASU and its impact on the consolidated financial statements.

Acquisition (Notes)

9 Months Ended

Sep. 30, 2014

Business Combinations [Abstract]

Mergers, Acquisitions and Dispositions Disclosures [Text Block]

Acquisition

On May 8, 2014, NeoStem closed (the “Closing”) its acquisition of CSC (the “CSC Acquisition”), pursuant to the terms of the Agreement and Plan of Merger, dated as of April 11, 2014 (the “Merger Agreement”), by and among NeoStem and its acquisition subsidiaries (collectively, "Subco"), CSC, and Jason Livingston, solely in his capacity as CSC stockholder representative (together with his permitted successors, the “CSC Representative”). At Closing, Fortis Advisors LLC succeeded to the duties of the CSC Representative pursuant to the Merger Agreement.

Pursuant to the Merger Agreement, on the Closing Date, Subco was merged with CSC (the “Merger”), with Subco surviving the Merger as a wholly-owned subsidiary of NeoStem. At Closing, Subco changed its legal name to NeoStem Oncology, LLC.

CSC has deep expertise in stem cell biology and is engaged in the development of therapies using a patient’s own, i.e., autologous, cells, with development efforts primarily directed at immunotherapies for cancer. Its most advanced program is a targeted cancer immunotherapy called NBS20, also referred to as DC/TC (dendritic cell/tumor cell), which uses patients’ own tumor cells to maximize the ability of their immune system to identify and eliminate the cancer initiating cells that are capable of reconstituting or developing new tumors (i.e., “cancer stem cells” or “replicating cells”). The current focus of that program is the treatment of metastatic melanoma. As a result of encouraging Phase 2 data, the Company initiated its Intus Phase 3 clinical trial in the fourth quarter of 2014, with enrollment expected to begin in the first quarter of 2015. The protocol for this study is the subject of a Special Protocol Assessment (“SPA”) and the immunotherapy has been granted Fast Track designation, as well as Orphan Drug designation.

Aggregate Merger Consideration

Pursuant to the terms of the Merger Agreement, all shares of CSC common stock (“CSC Common Stock”) and CSC preferred stock (“CSC Preferred Stock”, and collectively with the CSC Common Stock, the “CSC Capital Stock”) outstanding immediately prior to the Closing, and all outstanding unexercised options to purchase CSC Common Stock (“CSC Options”) (treated as if a net exercise had occurred), were canceled and converted into the right to receive, in the aggregate (and giving effect to the liquidation preferences accorded to the CSC Preferred Stock):

(1)An aggregate of 5,329,593 shares of NeoStem common stock (subject to payment of nominal cash in lieu of fractional shares) (the “Closing Merger Consideration”).

(2)if payable after the Closing, certain payments in an amount of up to $90.0 million in the aggregate, payable in shares of NeoStem Common Stock or cash, in NeoStem’s sole discretion, in the event of the successful completion of certain milestone events in connection with the CSC business being acquired by NeoStem (the “Milestone Payments”, and together with the Closing Merger Consideration, the “Merger Consideration”).

The fair value of the net assets acquired in the CSC Acquisition was $19.4 million. The fair value of the consideration paid by NeoStem was valued at $33.5 million, resulting in the recognition of goodwill in the amount of $14.1 million. The consideration paid was comprised of equity issued and milestone payments. The fair value of the equity issued by NeoStem was valued at $21.6 million. The fair value of the milestone payments was valued at $11.9 million, and is contingent on the achievement of certain milestones associated with the future development of the acquired programs. Such contingent consideration has been classified as a liability and will be subject to remeasurement at the end of each reporting period.

The preliminary fair value of assets acquired and liabilities assumed on May 8, 2014 is as follows (in thousands):



Cash and cash equivalents	$	51.2
Accounts receivable trade, net	45.1
Prepaids and other current assets	19.2
Property, plant and equipment, net	1,040.9
Other assets	201.0
Goodwill	14,091.7
In-Process R&D	34,290.0
Accounts payable	(333.1		)
Accrued liabilities	(2,014.1		)
Deferred tax liability	(13,901.2		)
	$	33,490.7

The total cost of the acquisition, which is still preliminary, has been allocated to the assets acquired and the liabilities assumed based upon their estimated fair values at the date of the acquisition. As of September 30, 2014, the preliminary fair values of the equity issued by NeoStem was reduced by $2.9 million, and the preliminary fair value of the milestone payments was increased by $1.1 million. In addition, the preliminary fair values of the In-Process R&D and Goodwill acquired were reduced by $ 1.5 million and $0.3 million, respectively, and the deferred tax liability assumed was decreased by $0.6 million. The estimated fair value determinations and purchase price allocation continues to be subject to revision based on additional valuation work that is being conducted. The final allocation is pending the receipt of a third-party valuation and the completion of the Company’s internal review, which is expected during the fourth quarter of 2014.

For the period since the CSC Acquisition (May 9, 2014 to September 30, 2014), NeoStem recorded $0.03 million in revenues and a net loss of approximately $5.4 million or $0.17 basic and diluted loss per share attributable to CSC.

Pro Forma Financial Information

The following supplemental table presents unaudited consolidated pro forma financial information as if the closing of the acquisition of CSC had occurred on January 1, 2013 (in thousands, except per share amounts):



	Nine Months Ended September 30, 2014
	(As Reported)			(Proforma)

Revenues	$	12,662		$	13,373
Net loss	$	(43,776	)	$	(46,273	)
Net loss attributable to NeoStem	$	(43,262	)	$	(45,759	)
Net loss per share attributable to NeoStem	$	(1.37	)	$	(1.24	)



	Three Months Ended September 30, 2013						Nine Months Ended September 30, 2013
	(As Reported)			(Proforma)			(As Reported)			(Proforma)

Revenues	$	3,707		$	3,893		$	10,590		$	11,175
Net loss	$	(9,277	)	$	(10,586	)	$	(26,767	)	$	(30,549	)
Net loss attributable to NeoStem	$	(9,071	)	$	(10,380	)	$	(26,447	)	$	(30,229	)
Net loss per share attributable to NeoStem	$	(0.45	)	$	(0.41	)	$	(1.43	)	$	(1.27	)

The unaudited supplemental pro forma financial information should not be considered indicative of the results that would have occurred if the acquisition of CSC had been consummated on January 1, 2013, nor are they indicative of future results.

Available-for-Sale-Securities (Notes)

9 Months Ended

Sep. 30, 2014

Available-for-sale Securities [Abstract]

Cash, Cash Equivalents, and Marketable Securities [Text Block]

Available-for-Sale-Securities

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):



	September 30, 2014
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Money market funds	$	17,512.9	$	—	$	—	$	17,512.9
Municipal debt securities	970.0		0.1		—		970.1
Total	$	18,482.9	$	0.1	$	—	$	18,483.0

Estimated fair values of available-for-sale securities are generally based on prices obtained from commercial pricing services. The following table summarizes the classification of the available-for-sale debt securities on our Consolidated Balance Sheets (in thousands):



	September 30, 2014
Cash and cash equivalents	$	17,817.9
Marketable securities	665.1
Total	$	18,483.0

The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):



	September 30, 2014
	Amortized Cost		Estimated Fair Value
Less than one year	$	18,482.9	$	18,483.0
Greater than one year	—		—
Total	$	18,482.9	$	18,483.0

Inventories	9 Months Ended
Inventories	Sep. 30, 2014
Inventories [Abstract]
Inventory Disclosure [Text Block]	Inventories Inventories, primarily representing work in process for costs incurred on projects at PCT that have not been completed, were $2.1 million and $1.3 million as of September 30, 2014 and December 31, 2013, respectively. The Company also has deferred revenue of approximately $3.3 million and $1.5 million of advance billings received as of September 30, 2014 and December 31, 2013, respectively, related to these contracts.

Loss Per Share

9 Months Ended

Sep. 30, 2014

Loss Per Share [Abstract]

Loss Per Share [Text Block]

Loss Per Share

For the nine months ended September 30, 2014 and 2013, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of loss per share as they are anti-dilutive. At September 30, 2014 and 2013, the Company excluded the following potentially dilutive securities:



	September 30,
	2014	2013
Stock Options	4,459,923	2,840,668
Warrants	3,555,956	5,054,302
Restricted Shares	233,982	92,000

Fair Value Measurements

9 Months Ended

Sep. 30, 2014

Fair Value Measurements [Abstract]

Fair Value Disclosures [Text Block]

Fair Value Measurements

Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:

Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.

Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.

Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.

The Company classifies the fair value of the warrant derivative liabilities as level 3 inputs. These inputs require material subjectivity because value is derived through the use of a lattice model that values the derivatives based on probability weighted discounted cash flows. In May 2014, the warrants expired and the value of the warrant derivative liabilities were written off and recorded in other expenses in our consolidated statement of operations.

The Company classifies the fair value of contingent consideration obligations as level 3 inputs. The Company has recognized contingent consideration obligations related to the following:

•

In October 2011, in connection with the Company's acquisition of Amorcyte, contingent consideration obligations were recognized relating to earn out payments equal to 10% of the net sales of the lead product candidate NBS10 (in the event of and following the date of first commercial sale of NBS10), provided that in the event NeoStem sublicenses NBS10, the applicable earn out payment will be equal to 30% of any sublicensing fees, and provided further that NeoStem will be entitled to recover direct out-of-pocket clinical development costs not previously paid or reimbursed and any costs, expenses, liabilities and settlement amounts arising out of claims of patent infringement or otherwise challenging Amorcyte’s right to use intellectual property, by reducing any earn out payments due by 50% until such costs have been recouped in full (the “Earn Out Payments”). The contingent consideration fair value increased from $9.5 million as of December 31, 2013 to $10.1 million as of September 30, 2014. The change in estimated fair value is based on the impact of the time progression through the Preserve AMI Phase 2 clinical trial from December 31, 2013 to September 30, 2014, and has been recorded in other expenses in our consolidated statement of operations.

•

In May 2014, in connection with the Company's acquisition of CSC, contingent consideration obligations were recognized relating to milestone payments of up to $90.0 million, based on the achievement of certain milestones associated with the future development of the acquired programs. The contingent consideration fair value recognized in the acquisition in May 2014 was $11.9 million. The contingent consideration fair value increased to $12.4 million as of September 30, 2014. The change in estimated fair value is based on changes in assumptions regarding the timing of certain milestone achievements, as well as the time progression to reach those milestones as of September 30, 2014, and has been recorded in other expenses in our consolidated statement of operations.

The fair value of contingent consideration obligations is based on discounted cash flow models using a probability-weighted income approach. The measurements are based upon unobservable inputs supported by little or no market activity based on our own assumptions and experience. The Company bases the timing to complete the development and approval programs on the current development stage of the product and the inherent difficulties and uncertainties in developing a product candidate, such as obtaining U.S. Food and Drug Administration (FDA) and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.

The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2014, and December 31, 2013 (in thousands):



	September 30, 2014								December 31, 2013
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Marketable securities - available for sale	$	—	$	665.1	$	—	$	665.1	$	—	$	—	$	—	$	—
	$	—	$	665.1	$	—	$	665.1	$	—	$	—	$	—	$	—

Liabilities:
Warrant derivative liabilities	$	—	$	—	$	—	$	—	$	—	$	—	$	23.2	$	23.2
Contingent consideration	—		—		22,430.0		22,430.0		—		—		9,450.0		9,450.0
	$	—	$	—	$	22,430.0	$	22,430.0	$	—	$	—	$	9,473.2	$	9,473.2

For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the nine months ended September 30, 2014 by type of instrument (in thousands):



	Nine Months Ended
	September 30, 2014
	Warrants			Contingent Consideration		Total
Beginning liability balance	$	23.2		$	9,450.0	$	9,473.2

Amount issued in acquisition	—			11,890.0		11,890.0
Change in fair value recorded in earnings	—			1,090.0		1,090.0
Expiration	(23.2		)	—		(23.2		)

Ending liability balance	$	—		$	22,430.0	$	22,430.0

Some of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate fair value due to their liquid or short-term nature, such as cash and cash equivalents, accounts receivable, accounts payable. Our long-term debt and notes payable are carried at cost and approximate fair value due to their variable or fixed interest rates, which are consistent with the interest rates in the market.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Goodwill and Other Intangible Assets

9 Months Ended

Sep. 30, 2014

Goodwill and Other Intangible Assets [Abstract]

Goodwill and Intangible Assets [Text Block]

Goodwill and Other Intangible Assets

The following table summarizes the changes in the carrying amount of goodwill (in thousands):



	Total
Balance as of December 31, 2013	$	11,117.8
Goodwill resulting from the acquisition of CSC	14,091.5
Balance as of September 30, 2014	$	25,209.3

The Company's intangible assets and related accumulated amortization as of September 30, 2014 and December 31, 2013 consisted of the following (in thousands):



		September 30, 2014							December 31, 2013
	Useful Life	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer list	10 years	$	1,000.0	$	(370.1	)	$	629.9	$	1,000.0	$	(295.1	)	$	704.9
Manufacturing technology	10 years	3,900.0		(1,443.4		)	2,456.6		3,900.0		(1,150.9		)	2,749.1
Tradename	10 years	800.0		(296.1		)	503.9		800.0		(236.1		)	563.9
In process R&D	Indefinite	43,690.0		—			43,690.0		9,400.0		—			9,400.0
Patent rights	19 years	669.0		(237.7		)	431.3		669.0		(211.3		)	457.7
Total Intangible Assets		$	50,059.0	$	(2,347.3	)	$	47,711.7	$	15,769.0	$	(1,893.4	)	$	13,875.6

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):



	Nine Months Ended September 30,
	2014		2013
Cost of revenue	$	237.6	$	292.5
Research and development	81.3		26.4
Selling, general and administrative	135.0		135.0
Total	$	453.9	$	453.9

Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands):



2014	$	151.3
2015	605.2
2016	605.2
2017	605.2
2018	605.2
Thereafter	45,139.6
	$	47,711.7

Accrued Liabilities

9 Months Ended

Sep. 30, 2014

Accrued Liabilities [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Accrued Liabilities

Accrued liabilities as of September 30, 2014 and December 31, 2013 were as follows (in thousands):



	September 30, 2014		December 31, 2013
Salaries, employee benefits and related taxes	$	1,435.6	$	2,325.8
Professional fees	608.2		544.8
License fees	100.0		500.0
Other	674.8		647.4
	$	2,818.6	$	4,018.0

Debt

9 Months Ended

Sep. 30, 2014

Debt [Abstract]

Debt Disclosure [Text Block]

Debt

Notes Payable

As of September 30, 2014 and December 31, 2013, the Company had notes payable of approximately $2.0 million and $0.9 million, respectively. The notes relate to certain insurance policies and equipment financings, require monthly payments, and mature within one to three years.

Long-Term Debt

On September 26, 2014, the Company entered into a loan and security agreement (the “Loan and Security Agreement”) with Oxford Finance LLC (together with its successors and assigns, the “Lender”) pursuant to which the Lender has agreed to lend the Company up to $20.0 million. Upon entering into the Loan and Security Agreement, the Lender disbursed $15.0 million (“Term Loan A”). Under the terms of the Loan and Security Agreement, during the Second Draw Period (as defined below), the Company may, subject to certain conditions, borrow from Lender an additional $5.0 million (“Term Loan B”, together with Term Loan A, the “Term Loans”). The “Second Draw Period” is the period of time: (a) commencing on the date that Lender receives evidence in a form and substance satisfactory to Lender that the Company has entered into a strategic arrangement with respect to the Company’s NBS10 product candidate for ST Elevation Myocardial Infarction and receives an upfront payment of not less than $10.0 million in connection therewith, and (b) ending on the earlier of September 19, 2015 or the occurrence of an event of default under the Term Loans. After repayment of all outstanding amounts due under two loans from TD Bank, N.A. in the amount of approximately $3.1 million, and deductions for debt offering/issuance costs and interim period interest, the net proceeds from Term Loan A were $11.7 million. The debt offering/issuance costs have been recorded as debt issuance costs in other assets in the consolidated balance sheet, and will be amortized to interest expense throughout the life of the Term Loans using the effective interest rate method. The proceeds from the Term Loans may be used to satisfy the Company’s future working capital needs, including the development of its cell therapy product candidates.

The Company will make interest only payments on the outstanding amount of Term Loans on a monthly basis until October 1, 2015 at a rate of 8.50% per annum; provided however, such interest-only period may be extended to April 1, 2016, in the event of either (1) the signing of a partnership for (x) traumatic brain injury indication for the Company's Ischemic Repair Program or for its VSEL^TM Program or (y) critical limb ischemia indication for its Ischemic Repair Program; or (2) the initiation of the Intus Phase 3 study evaluating the Company's product candidate NBS20 (also referred to as DC/TC) in patients with Stage IV or recurrent Stage III metastatic melanoma. Commencing on the date that principal payments commence, the Company will make consecutive monthly payments of principal and interest based upon a repayment schedule equal to (a) 36 months, if the Term Loans begin amortizing on October 1, 2015, or (b) 30 months, if the Term Loans begin amortizing on April 1, 2016. The Term Loans mature on September 1, 2018. At its option, the Company may prepay all amounts owed under the Loan and Security Agreement (including all accrued and unpaid interest), subject to a prepayment fee that is determined based on the date the loan is prepaid. The Company is also required to pay Lender a final payment fee equal to 8% of the Term Loan A and Term Loan B (if disbursed). The final payment fee will be amortized to interest expense throughout the life of the Term Loans using the effective interest rate method. The Company paid a facility fee in the amount of $100,000 in connection with Term Loan A.

Under the Loan and Security Agreement and a related mortgage, the Company granted to Lender a security interest in all of the Company’s real property and personal property now owned or hereafter acquired, excluding intellectual property, and certain other assets and exemptions. The Company also entered into a Mortgage and Absolute Assignment of Leases and Rents (the "Mortgage"). The Company also granted Lender a security interest in the shares of the Company’s subsidiaries. The Loan and Security Agreement restricts the ability of the Company to: (a) convey, lease, sell, transfer or otherwise dispose of any part of its business or property; and (b) incur any additional indebtedness. The Loan and Security Agreement provides for standard indemnification of Lender and contains representations, warranties and certain covenants of the Company. Upon the occurrence of an event of default by the Company under the Loan and Security Agreement, Lender will have customary acceleration, collection and foreclosure remedies. There are no financial covenants associated to the Loan and Security Agreement. As of September 30, 2014, the Company was in compliance with all covenants under the Loan and Security Agreement.

Estimated future principal payments, interest, and fees due under the Loan and Security Agreement are as follows:



Years Ending December 31,	(in millions)
2014	$	0.2
2015	2.4
2016	5.7
2017	5.7
2018	5.5
Total	$	19.5

During the nine months ended September 30, 2014, the Company recognized $17,708 of interest expense related to the Loan and Security Agreement.

Mortgages Payable

In October 2007, PCT issued a note to borrow $3.1 million (the “First Mortgage”) in connection with its $3.8 million purchase of condominium units in an existing building in Allendale, New Jersey (the “Property”). The First Mortgage was payable in 239 consecutive monthly payments of principal and interest, based on a 20 year amortization schedule; and one final payment of all outstanding principal plus accrued interest then due. The monthly installment was $20,766, which includes interest at an initial rate of 5.00%; the interest rate and monthly installments payments were subject to adjustment on October 1, 2017. The outstanding balance was approximately $2.5 million at December 31, 2013. In connection with the Loan and Security Agreement signed in September 2014, the remaining $2.4 million mortgage obligation was repaid, along with accrued interest and mortgage termination fees.

In December 2010 PCT Allendale, a wholly-owned subsidiary of PCT, entered into a note for a second mortgage in the amount of 1.0 million (the "Second Mortgage") on the Allendale Property with TD Bank, N.A. The initial guarantors of the Second Mortgage were PCT, DomaniCell (a wholly-owned subsidiary of PCT, now known as NeoStem Family Storage, LLC), Regional Cancer Care Associates LLC and certain of its partners. The Second Mortgage was for 124 months at a fixed rate of 6% for the first 64 months. The outstanding balance was approximately $0.8 million at December 31, 2013. In connection with the Loan and Security Agreement signed in September 2014, the remaining $0.7 million mortgage obligation was repaid, along with accrued interest and mortgage termination fees.

Prior to the full repayment of the mortgages in September 2014, the Company modified both the First Mortgage and Second Mortgage with TD Bank, N.A. in December 2013, whereby prior guarantors were released (see Note 14) and replaced with NeoStem, PCT, and NeoStem Family Storage, LLC.

Shareholders' Equity

9 Months Ended

Sep. 30, 2014

Shareholders’ Equity [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Shareholders' Equity

Reverse Stock Split

On June 28, 2013, pursuant to prior shareholder authorization, the Company’s board of directors unanimously approved a 1-for-10 reverse stock split of the Company’s common stock, which the Company effected on July 16, 2013. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods to give retroactive effect to the reverse stock split. The shares of common stock retained a par value of $0.001 per share. Accordingly, the stockholders’ deficit reflects the reverse stock split by reclassifying from “common stock” to “additional paid-in capital” an amount equal to the par value of the decreased shares resulting from the reverse stock split.

Option Plan Increase

At our Annual Stockholders Meeting held on October 6, 2014, the stockholders approved an amendment to the Company's Amended and Restated 2009 Equity Compensation Plan ("the Plan") to increase the number of shares of common stock authorized for issuance thereunder by 3,000,000, increasing the maximum aggregate number of shares that may be issued under the Plan to 8,995,000.

Equity Issuances

In September 2011, the Company entered into a common stock purchase agreement (the “Initial Purchase Agreement”) with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which provided that Aspire Capital was committed to purchase up to an aggregate of $20.0 million worth of shares of the Company’s common stock over the 24-month term. In August, 2012, the Initial Purchase Agreement was extended for an additional 24-month term through September 2015. During the three months ended March 31, 2014, the Company issued 0.8 million shares of Common Stock under the provisions the Initial Purchase Agreement with Aspire for gross proceeds of approximately $5.6 million. As of March 31, 2014, the full $20.0 million worth of shares of the Company's stock had been issued under the Initial Purchase Agreement.

In March 2014, the Company entered into a new common stock purchase agreement (the “Purchase Agreement”) with Aspire Capital, which provides that, subject to certain terms and conditions, Aspire Capital is committed to purchase up to an aggregate of $30.0 million worth of shares of the Company’s common stock over the 24-month term. At the Company’s discretion, it may present Aspire Capital with purchase notices from time to time to purchase the Company’s common stock, provided certain price and other requirements are met. The purchase price for the shares of stock is based upon one of two formulas set forth in the Purchase Agreement depending on the type of purchase notice the Company submits to Aspire Capital, and is based on market prices of the Company’s common stock (in the case of regular purchases) or a discount of 5% applied to volume weighted average prices (in the case of VWAP purchases), in each case as determined by parameters defined in the Purchase Agreement. As consideration for entering into the Purchase Agreement, we issued 150,000 shares of our common stock to Aspire Capital. During the nine months ended September 30, 2014, the Company issued 0.9 million shares of Common Stock under the provisions of the Purchase Agreement with Aspire for gross proceeds of approximately $5.6 million.

Option Exercises

During the nine months ended ended September 30, 2014, option holders exercised an aggregate of 48,987 options at exercise prices between of $5.20 and $6.20 per share for gross proceeds of approximately $0.3 million.

Warrant Exercises

During the nine months ended ended September 30, 2014, warrant holders exercised an aggregate of 333,250 warrants at exercise prices between $5.10 and $14.50 per share for gross proceeds of approximately $1.7 million.

Stock Options and Warrants

The following table summarizes the activity for stock options and warrants for the nine months ended September 30, 2014:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2013	2,932,191		$	11.19	6.81	$	1,658.1	4,898,266		$	16.50	2.63	$	1,811.0

Changes during the period:
Granted	2,102,525		$	6.85				2,722		$	12.26
Exercised	(48,987	)	$	5.53				(333,250	)	$	5.16
Forfeited	(262,954	)	$	6.54				(100,108	)	$	70.00
Expired	(262,852	)	$	15.18				(911,674	)	$	23.97
Outstanding at September 30, 2014	4,459,923		$	9.24	7.56	$	580.9	3,555,956		$	14.13	2.37	$	273.2
Vested at September 30, 2014 or expected to vest in the future	4,172,772		$	9.38	7.44	$	561.2	3,555,956		$	14.13	2.37	$	273.2
Vested at September 30, 2014	2,823,720		$	10.36	6.73	$	403.9	3,545,956		$	14.15	2.37	$	273.2

During the nine months ended September 30, 2014 and 2013, the Company issued warrants for services as follows ($ in thousands, except share data):



	Nine Months Ended September 30,
	2014		2013
Number of Common Stock Purchase Warrants Issued	—		20,407
Value of Common Stock Purchase Warrants Issued	$	—	$	70.5

Restricted Stock

During the nine months ended September 30, 2014 and 2013, the Company issued restricted stock for services as follows ($ in thousands, except share data):



	Nine Months Ended September 30,
	2014		2013
Number of Restricted Stock Issued	708,706		452,454
Value of Restricted Stock Issued	$	4,964.0	$	2,967.7

The weighted average estimated fair value of restricted stock issued for services in the nine months ended September 30, 2014 and 2013 was $7.00 and $6.56 per share, respectively. The fair value of the restricted stock was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock issuances are generally within one year.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Share-Based Compensation (Notes)

9 Months Ended

Sep. 30, 2014

Share-based Compensation [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Share-Based Compensation

Share-based Compensation

We utilize share-based compensation in the form of stock options, warrants and restricted stock. The following table summarizes the components of share-based compensation expense for the three and nine months ended September 30, 2014 and 2013 (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Cost of goods sold	$	55.9	$	88.8	$	292.6	$	233.7
Research and development	515.7		319.9		1,364.2		667.0
Selling, general and administrative	2,716.3		1,718.9		7,284.7		4,511.8
Total share-based compensation expense	$	3,287.9	$	2,127.6	$	8,941.5	$	5,412.5

Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at September 30, 2014 were as follows (dollars in thousands):



	Stock Options		Warrants		Restricted Stock
Unrecognized compensation cost	$	6,266.7	$	20.4	$	327.4
Expected weighted-average period in years of compensation cost to be recognized	4.94		0.79		0.31

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September 30, 2014 and 2013 were as follows (dollars in thousands):



	Stock Options				Warrants
	Nine Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Total fair value of shares vested	$	4,141.6	$	2,470.0	$	15.3	$	123.0
Weighted average estimated fair value of shares granted	$	4.67	$	4.30	$	—	$	3.45

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2014
Income Taxes [Abstract]
Income Tax Disclosure [Text Block]	Income Taxes As of December 31, 2013, the Company had approximately $110.6 million of Federal NOLs available to offset future taxable income expiring from 2025 through 2033. In accordance with Section 382 of the Internal Revenue code, the usage of the Company’s NOLs could be limited in the event of a change in ownership. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period when those temporary differences become deductible. If a change of ownership did occur there would be an annual limitation on the usage of the Company’s losses which are available through 2033. In assessing the realizability of deferred tax assets, including the net operating loss carryforwards ("NOLs"), the Company assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize its existing deferred tax assets. Based on its assessment, the Company has provided a full valuation allowance against its net deferred tax assets as their future utilization remains uncertain at this time. Deferred tax liabilities were $18.4 million and $4.4 million as of September 30, 2014 and December 31, 2013, respectively, and relate to the taxable temporary differences on (i) the goodwill recognized in the PCT acquisition in 2011, (ii) the in-process R&D intangible asset recognized in the Amorcyte acquisition in 2011, and (iii) the in-process R&D intangible asset recognized in the CSC acquisition in 2014. The taxable temporary difference associated with the goodwill, which is tax deductible and will be amortized over 15 years, will continue to increase the deferred tax liability balance over the amortization period, with an associated charge to the tax provision in each period. The deferred tax liabilities will only reverse when these indefinite-lived assets are sold, impaired, or reclassified from an indefinite-lived asset to a finite-lived asset. As of September 30, 2014, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2014
Related Party Transactions [Abstract]
Related Party Transactions [Text Block]	Related Party Transactions In December 2013, the Company modified both the First Mortgage and Second Mortgage with TD Bank, N.A. (see Note 10). Pursuant to the Loan Modifications, Andrew L. Pecora, M.D., Regional Cancer Care Associates LLC (Dr. Pecora’s medical practice), and certain partners in such practice, including Dr. Pecora, have been released as guarantors of the Second Mortgage Loan, and NeoStem has become a guarantor of the Loans pursuant to a Guaranty of Payment delivered by NeoStem to the Lender. Dr. Pecora currently serves as a NeoStem director, NeoStem’s Chief Visionary Officer, PCT’s Chief Medical Officer and Amorcyte’s Chief Scientific Officer.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Commitments and Contingencies

9 Months Ended

Sep. 30, 2014

Commitments and Contingencies [Abstract]

Commitments and Contingencies [Text Block]

Commitments and Contingencies

Lease Commitments

The Company leases offices, of which certain have escalation clauses and renewal options, and also leases equipment under certain noncancelable operating leases that expire from time to time through 2018. In January 2014, the Company signed a new lease for additional space at its current executive offices at 420 Lexington Avenue, New York, NY 10170. The new lease is believed to provide sufficient space for the near future and shall extend through 2018. This property is used as the Company's corporate headquarters. In connection with the CSC Acquisition on May 8, 2014, the Company assumed a facility lease in Irvine, California, with a termination at the end of 2017.

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of September 30, 2014 are as follows (in thousands):



Years ended	Operating Leases
2014	$	337.2
2015	1,162.5
2016	999.9
2017	699.8
2018	7.0
Total minimum lease payments	$	3,206.4

Expense incurred under operating leases was approximately $0.4 million and $0.3 million for the three months ended September 30, 2014 and 2013, respectively. Expense incurred under operating leases was approximately $0.9 million and $0.9 million for the nine months ended September 30, 2014 and 2013, respectively.

Contingencies

Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products. The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research.

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2014

Summary of Significant Accounting Policies [Abstract]

Schedule of Cash and Cash Equivalents [Table Text Block]

Cash and Cash Equivalents

Cash and cash equivalents include short-term, highly liquid, investments with maturities of ninety days or less when purchased.

Marketable Securities, Policy [Policy Text Block]

Marketable Securities

Receivables, Policy [Policy Text Block]

Accounts Receivable

Inventory Disclosure [Text Block]

Inventories

Goodwill and Intangible Assets, Policy [Policy Text Block]

Goodwill and Other Intangible Assets

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Clinical Services: The Company recognizes revenue for its (i) process development and (ii) clinical manufacturing services based on the terms of individual contracts.


•	persuasive evidence of an arrangement exists;


•	delivery has occurred or the services have been rendered;


•	the fee is fixed or determinable; and


•	collectability is probable.

New Accounting Pronouncements, Policy [Policy Text Block]

New Accounting Pronouncement

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References + Details

- Definition

Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.

+ References + Details

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

The Business (Tables)

9 Months Ended

Sep. 30, 2014

The Business [Abstract]

Subsidiary [Table Text Block]



Entity	Percentage of Ownership	Location
NeoStem, Inc.	Parent Company	United States of America
NeoStem Therapies, Inc.	100%	United States of America
Stem Cell Technologies, Inc.	100%	United States of America
Amorcyte, LLC	100%	United States of America
Progenitor Cell Therapy, LLC (PCT)	100%	United States of America
NeoStem Family Storage, LLC	100%	United States of America
Athelos Corporation (1)	90%	United States of America
PCT Allendale, LLC	100%	United States of America
NeoStem Oncology, LLC (2)	100%	United States of America

Acquisition (Tables)

9 Months Ended

Sep. 30, 2014

Business Combinations [Abstract]

Business Acquisition, Pro Forma Information [Table Text Block]



	Nine Months Ended September 30, 2014
	(As Reported)			(Proforma)

Revenues	$	12,662		$	13,373
Net loss	$	(43,776	)	$	(46,273	)
Net loss attributable to NeoStem	$	(43,262	)	$	(45,759	)
Net loss per share attributable to NeoStem	$	(1.37	)	$	(1.24	)



	Three Months Ended September 30, 2013						Nine Months Ended September 30, 2013
	(As Reported)			(Proforma)			(As Reported)			(Proforma)

Revenues	$	3,707		$	3,893		$	10,590		$	11,175
Net loss	$	(9,277	)	$	(10,586	)	$	(26,767	)	$	(30,549	)
Net loss attributable to NeoStem	$	(9,071	)	$	(10,380	)	$	(26,447	)	$	(30,229	)
Net loss per share attributable to NeoStem	$	(0.45	)	$	(0.41	)	$	(1.43	)	$	(1.27	)

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The preliminary fair value of assets acquired and liabilities assumed on May 8, 2014 is as follows (in thousands):



Cash and cash equivalents	$	51.2
Accounts receivable trade, net	45.1
Prepaids and other current assets	19.2
Property, plant and equipment, net	1,040.9
Other assets	201.0
Goodwill	14,091.7
In-Process R&D	34,290.0
Accounts payable	(333.1		)
Accrued liabilities	(2,014.1		)
Deferred tax liability	(13,901.2		)
	$	33,490.7

Available-for-Sale-Securities (Tables)

9 Months Ended

Sep. 30, 2014

Available-for-sale Securities [Abstract]

Schedule of Available-for-sale Securities Reconciliation [Table Text Block]

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our Consolidated Balance Sheets (in thousands):



	September 30, 2014
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Value
Money market funds	$	17,512.9	$	—	$	—	$	17,512.9
Municipal debt securities	970.0		0.1		—		970.1
Total	$	18,482.9	$	0.1	$	—	$	18,483.0

Marketable Securities [Table Text Block]



	September 30, 2014
Cash and cash equivalents	$	17,817.9
Marketable securities	665.1
Total	$	18,483.0

Investments Classified by Contractual Maturity Date [Table Text Block]

The following table summarizes our portfolio of available-for-sale debt securities by contractual maturity (in thousands):



	September 30, 2014
	Amortized Cost		Estimated Fair Value
Less than one year	$	18,482.9	$	18,483.0
Greater than one year	—		—
Total	$	18,482.9	$	18,483.0

Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2014

Loss Per Share [Abstract]

ScheduleOfDilutiveSecuritiesExcludedFromComputationOfEarningsPerShare [Table Text Block]

At September 30, 2014 and 2013, the Company excluded the following potentially dilutive securities:



	September 30,
	2014	2013
Stock Options	4,459,923	2,840,668
Warrants	3,555,956	5,054,302
Restricted Shares	233,982	92,000

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2014

Fair Value Measurements [Abstract]

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis, Valuation Techniques [Table Text Block]

•



	September 30, 2014								December 31, 2013
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Marketable securities - available for sale	$	—	$	665.1	$	—	$	665.1	$	—	$	—	$	—	$	—
	$	—	$	665.1	$	—	$	665.1	$	—	$	—	$	—	$	—

Liabilities:
Warrant derivative liabilities	$	—	$	—	$	—	$	—	$	—	$	—	$	23.2	$	23.2
Contingent consideration	—		—		22,430.0		22,430.0		—		—		9,450.0		9,450.0
	$	—	$	—	$	22,430.0	$	22,430.0	$	—	$	—	$	9,473.2	$	9,473.2

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the nine months ended September 30, 2014 by type of instrument (in thousands):



	Nine Months Ended
	September 30, 2014
	Warrants			Contingent Consideration		Total
Beginning liability balance	$	23.2		$	9,450.0	$	9,473.2

Amount issued in acquisition	—			11,890.0		11,890.0
Change in fair value recorded in earnings	—			1,090.0		1,090.0
Expiration	(23.2		)	—		(23.2		)

Ending liability balance	$	—		$	22,430.0	$	22,430.0

Goodwill and Other Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2014

Goodwill and Other Intangible Assets [Abstract]

Schedule of Goodwill [Table Text Block]

The following table summarizes the changes in the carrying amount of goodwill (in thousands):



	Total
Balance as of December 31, 2013	$	11,117.8
Goodwill resulting from the acquisition of CSC	14,091.5
Balance as of September 30, 2014	$	25,209.3

Schedule of Finite-Lived Intangible Assets by Major Class [Table Text Block]

The Company's intangible assets and related accumulated amortization as of September 30, 2014 and December 31, 2013 consisted of the following (in thousands):



		September 30, 2014							December 31, 2013
	Useful Life	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer list	10 years	$	1,000.0	$	(370.1	)	$	629.9	$	1,000.0	$	(295.1	)	$	704.9
Manufacturing technology	10 years	3,900.0		(1,443.4		)	2,456.6		3,900.0		(1,150.9		)	2,749.1
Tradename	10 years	800.0		(296.1		)	503.9		800.0		(236.1		)	563.9
In process R&D	Indefinite	43,690.0		—			43,690.0		9,400.0		—			9,400.0
Patent rights	19 years	669.0		(237.7		)	431.3		669.0		(211.3		)	457.7
Total Intangible Assets		$	50,059.0	$	(2,347.3	)	$	47,711.7	$	15,769.0	$	(1,893.4	)	$	13,875.6

Schedule of Amortization Expense [Table Text Block]

Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):



	Nine Months Ended September 30,
	2014		2013
Cost of revenue	$	237.6	$	292.5
Research and development	81.3		26.4
Selling, general and administrative	135.0		135.0
Total	$	453.9	$	453.9

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands):



2014	$	151.3
2015	605.2
2016	605.2
2017	605.2
2018	605.2
Thereafter	45,139.6
	$	47,711.7

Accrued Liabilities Accrued Liabilities (Tables)

9 Months Ended

Sep. 30, 2014

Accrued Liabilities [Abstract]

Schedule of Accrued Liabilities [Table Text Block]

Accrued liabilities as of September 30, 2014 and December 31, 2013 were as follows (in thousands):



	September 30, 2014		December 31, 2013
Salaries, employee benefits and related taxes	$	1,435.6	$	2,325.8
Professional fees	608.2		544.8
License fees	100.0		500.0
Other	674.8		647.4
	$	2,818.6	$	4,018.0

Debt Long term debt (Tables)

9 Months Ended

Sep. 30, 2014

Long-term Debt, Unclassified [Abstract]

Schedule of Maturities of Long-term Debt [Table Text Block]

Estimated future principal payments, interest, and fees due under the Loan and Security Agreement are as follows:



Years Ending December 31,	(in millions)
2014	$	0.2
2015	2.4
2016	5.7
2017	5.7
2018	5.5
Total	$	19.5

Shareholders' Equity (Tables)

9 Months Ended

Sep. 30, 2014

Shareholders’ Equity [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes the activity for stock options and warrants for the nine months ended September 30, 2014:



	Stock Options							Warrants
	Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)		Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding at December 31, 2013	2,932,191		$	11.19	6.81	$	1,658.1	4,898,266		$	16.50	2.63	$	1,811.0

Changes during the period:
Granted	2,102,525		$	6.85				2,722		$	12.26
Exercised	(48,987	)	$	5.53				(333,250	)	$	5.16
Forfeited	(262,954	)	$	6.54				(100,108	)	$	70.00
Expired	(262,852	)	$	15.18				(911,674	)	$	23.97
Outstanding at September 30, 2014	4,459,923		$	9.24	7.56	$	580.9	3,555,956		$	14.13	2.37	$	273.2
Vested at September 30, 2014 or expected to vest in the future	4,172,772		$	9.38	7.44	$	561.2	3,555,956		$	14.13	2.37	$	273.2
Vested at September 30, 2014	2,823,720		$	10.36	6.73	$	403.9	3,545,956		$	14.15	2.37	$	273.2

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

During the nine months ended September 30, 2014 and 2013, the Company issued warrants for services as follows ($ in thousands, except share data):



	Nine Months Ended September 30,
	2014		2013
Number of Common Stock Purchase Warrants Issued	—		20,407
Value of Common Stock Purchase Warrants Issued	$	—	$	70.5

Restricted Stock [Table Text Block]

During the nine months ended September 30, 2014 and 2013, the Company issued restricted stock for services as follows ($ in thousands, except share data):



	Nine Months Ended September 30,
	2014		2013
Number of Restricted Stock Issued	708,706		452,454
Value of Restricted Stock Issued	$	4,964.0	$	2,967.7

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

Share-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2014

Share-based Compensation [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The following table summarizes the components of share-based compensation expense for the three and nine months ended September 30, 2014 and 2013 (in thousands):



	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Cost of goods sold	$	55.9	$	88.8	$	292.6	$	233.7
Research and development	515.7		319.9		1,364.2		667.0
Selling, general and administrative	2,716.3		1,718.9		7,284.7		4,511.8
Total share-based compensation expense	$	3,287.9	$	2,127.6	$	8,941.5	$	5,412.5

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]



	Stock Options		Warrants		Restricted Stock
Unrecognized compensation cost	$	6,266.7	$	20.4	$	327.4
Expected weighted-average period in years of compensation cost to be recognized	4.94		0.79		0.31

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]

Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September 30, 2014 and 2013 were as follows (dollars in thousands):



	Stock Options				Warrants
	Nine Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Total fair value of shares vested	$	4,141.6	$	2,470.0	$	15.3	$	123.0
Weighted average estimated fair value of shares granted	$	4.67	$	4.30	$	—	$	3.45

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2014

Commitments and Contingencies [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of September 30, 2014 are as follows (in thousands):



Years ended	Operating Leases
2014	$	337.2
2015	1,162.5
2016	999.9
2017	699.8
2018	7.0
Total minimum lease payments	$	3,206.4

The Business (Details) - USD ($)	9 Months Ended
The Business (Details) - USD ($)	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2011
The Company [Line Items]
Subsidiary, Ownership Interest by Parent	90.00%		80.10%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	10.00%		19.90%
Change in Ownership in Subsidiary	$ 0	$ 0
Noncontrolling Interest [Member]
The Company [Line Items]
Change in Ownership in Subsidiary	$ 86,617	$ 111,680

The Business Principal of consolidation (Details)	9 Months Ended
The Business Principal of consolidation (Details)	Sep. 30, 2014	Mar. 31, 2011
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	90.00%	80.10%
NeoStem, Inc. [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Minority Interest Ownership Percentage By Parent [String]	Parent Company
NeoStem Therapies, Inc [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Stem Cell Technologies, Inc [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Amorcyte, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Progenitor Cell Therapy, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
NeoStem Family Storage, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
Athelos Corporation [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	90.00%
PCT Allendale, LLC [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%
NeoStem Oncology [Member] \| UNITED STATES
Schedule of Subisidiary [Line Items]
Subsidiary, Ownership Interest by Parent	100.00%

Summary of Significant Accounting Policies (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Summary of Significant Accounting Policies [Abstract]
Clinical Services Reimbursement	$ 1.0	$ 0.6	$ 2.8	$ 1.4

Acquisition (Details) - USD ($)	3 Months Ended		5 Months Ended	9 Months Ended
Acquisition (Details) - USD ($)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2013	May 08, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Asset at Fair Value, Changes in Fair Value Resulting from Changes in Assumptions	$ (2,900,000)
Change in acquisition-related contingent consideration	1,100,000			$ 1,090,000	$ 0
Impairment of Intangible Assets (Excluding Goodwill)	(1,500,000)
Goodwill, Period Increase (Decrease)	(300,000)
Revenues	4,117,783	$ 3,706,918		12,662,290	10,590,237
Net loss	$ (17,176,644)	$ (9,276,601)		$ (43,776,220)	(26,766,572)
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual			$ 30,000
Common Stock, Shares, Issued	35,485,523		35,485,523	35,485,523		5,329,593	27,196,537
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High						$ 90,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net						19,400,000
Acquisition-related contingent consideration	$ 22,430,000		$ 22,430,000	$ 22,430,000		11,900,000	$ 9,450,000
Business Acquisition, Transaction Costs						33,500,000
Cash and cash equivalents						51,200
Accounts receivable, net of allowance for doubtful accounts of $390,118 and $391,829 at March 31, 2014 and December 31, 2013, respectively						45,100
Prepaid expenses and other current assets						19,200
Property, plant and equipment, net						1,040,900
Other assets						201,000
Goodwill	25,209,336		25,209,336	25,209,336		14,091,700	11,117,770
Equity Issued in Business Combination, Fair Value Disclosure						21,600,000
Intangible assets, net						34,290,000
Accounts Payable, Current						(333,100)
Accrued Liabilities, Current						(2,014,100)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent						(13,901,200)
Deferred Tax Liabilities, Net, Noncurrent	$ 600,000			$ (142,183)	$ (492,325)
Business Acquisition, Pro Forma Net Income (Loss)			$ (5,400,000)
Basic and diluted loss per share attributable to NeoStem, Inc. common stockholders	$ (0.48)	$ (0.45)	$ (0.17)	$ (1.37)	$ (1.43)
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net						$ 33,490,700
NeoStem Oncology [Member]
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Revenue		$ 3,893,000		$ 13,373,000	$ 11,175,000
Business Acquisition, Pro Forma Net Income (Loss)		(10,586,000)		(46,273,000)	(30,549,000)
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual		$ (10,380,000)		$ (45,759,000)	$ (30,229,000)
Business Acquisition, Pro Forma Earnings Per Share, Diluted		$ (0.41)		$ (1.24)	$ (1.27)
NeoStem, Inc. [Member]
Business Acquisition [Line Items]
Revenues		$ 3,707,000		$ 12,662,000	$ 10,590,000
Net loss		(9,277,000)		(43,776,000)	(26,767,000)
Net Income (Loss) Attributable to Parent		$ (9,071,000)		(43,262,000)	$ (26,447,000)
Goodwill	$ 25,209.3		$ 25,209.3	$ 25,209.3			$ 11,117.8
Basic and diluted loss per share attributable to NeoStem, Inc. common stockholders		$ (0.45)		$ (1.37)	$ (1.43)

Available-for-Sale-Securities Schedule of Available-for-sale Securites Reconciliation (Details)	Sep. 30, 2014 USD ($)
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	$ 18,482,900
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	100
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0
Certificates of Deposit, at Carrying Value	18,483,000
Municipal Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	970,000
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	100
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0
Certificates of Deposit, at Carrying Value	970,100
Money Market Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities, Amortized Cost Basis	17,512,900
Deferred Tax Liabilities, Unrealized Gains on Trading Securities	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	0
Certificates of Deposit, at Carrying Value	$ 17,512,900

Available-for-Sale-Securities Classification of the available-for-sale securities (Details)	Sep. 30, 2014 USD ($)
Available-for-sale Securities [Abstract]
Cash	$ 17,817,900
Marketable securities	665,100
Total	$ 18,483,000

Available-for-Sale-Securities Available-for-sale Securities by Contractual Maturity (Details)	Sep. 30, 2014 USD ($)
Available-for-sale Securities [Abstract]
Less than one year, Amortized Cost	$ 18,482,900
Less than one year, Fair Value	18,483,000
Amortized Cost	18,482,900
Estimated Fair Value	$ 18,483,000

Inventories (Details) - USD ($)	Sep. 30, 2014	Dec. 31, 2013
Schedule of Inventory [Line Items]
Inventory	$ 2,142,302	$ 1,270,223
Multiple Stage Contracts [Member]
Schedule of Inventory [Line Items]
Deferred Revenue	$ 3,300,000	$ 1,500,000

Loss Per Share (Details) - shares	9 Months Ended
Loss Per Share (Details) - shares	Sep. 30, 2014	Sep. 30, 2013
Warrants
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	3,555,956	5,054,302
Stock Options [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	4,459,923	2,840,668
Restricted Stock [Member]
Class of Stock [Line Items]
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	233,982	92,000

Fair Value Measurements Fair value hierarchy the Company’s financial assets and liabilities (Details) - USD ($)	9 Months Ended
	Sep. 30, 2014	May 08, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration	$ 22,430,000	$ 11,900,000	$ 9,450,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		$ 90,000,000
Business Combination, Consideration Transferred, Liabilities Incurred	11,890,000
Available-for-sale Securities	665,100		0
Marketable securities	665,112		0
Warrant Derivative Liabilities	0		23,200
Accrued Liabilities and Other Liabilities	22,430,000		9,473,200
Business Combination, Liabilities Arising from Contingencies, Amount Recognized	12,400,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0		0
Marketable securities	0		0
Warrant Derivative Liabilities	0		0
Contingent Consideration Classified as Equity, Fair Value Disclosure	0		0
Accrued Liabilities and Other Liabilities	0		0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	665,100		0
Marketable securities	665,100		0
Warrant Derivative Liabilities	0		0
Contingent Consideration Classified as Equity, Fair Value Disclosure	0		0
Accrued Liabilities and Other Liabilities	0		0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Available-for-sale Securities	0		0
Marketable securities	0		0
Warrant Derivative Liabilities	0		23,200
Contingent Consideration Classified as Equity, Fair Value Disclosure	22,430,000		9,450,000
Accrued Liabilities and Other Liabilities	22,430,000		9,473,200
Assets, Total [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities	665,100		0
Contingent Consideration Classified as Equity [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration	22,430,000		9,450,000
Business Combination, Consideration Transferred, Liabilities Incurred	11,890,000
Amorcyte, LLC [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Acquisition-related contingent consideration	10,100,000		9,500,000
Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant Derivative Liabilities	0		23,200
Contingent Consideration Classified as Equity [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent Consideration Classified as Equity, Fair Value Disclosure	$ 22,430,000		$ 9,450,000

Fair Value Measurements Financial instruments with significant Level 3 inputs (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	May 08, 2014	Dec. 31, 2013	Dec. 31, 2011
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of Net Sales							10.00%
Percentage of license cost							30.00%
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Warrant Derivative Liabilities	$ 0	$ 0		$ 0		$ 23,200
Acquisition-related contingent consideration				22,430,000	$ 11,900,000	9,450,000
Accrued Liabilities and Other Liabilities				22,430,000		9,473,200
Business Combination, Consideration Transferred, Liabilities Incurred		11,890,000
Change in acquisition-related contingent consideration	1,100,000	1,090,000	$ 0
Fair Value, Option, Changes in Fair Value, Gain (Loss)		1,090,000
Expiration		(23,200)
Warrant Derivative Liabilities	$ 0	0
Warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Warrants Issued During Period, Value		0
Fair Value Adjustment of Warrants		0
Expiration		(23,200)
Contingent Consideration Classified as Equity [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Acquisition-related contingent consideration				$ 22,430,000		$ 9,450,000
Business Combination, Consideration Transferred, Liabilities Incurred		11,890,000
Change in acquisition-related contingent consideration		1,090,000
Expiration		$ 0

Goodwill and Other Intangible Assets Intangible Assets and Related Accumulated Amortization (Details) - USD ($)	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Goodwill [Roll Forward]
Goodwill	$ 11,117,770
Goodwill	25,209,336
Finite-Lived Intangible Assets, Gross	50,059,000	$ 15,769,000
Finite-Lived Intangible Assets, Accumulated Amortization	(2,347,300)	(1,893,400)
Finite-Lived Intangible Assets, Future Amortization Expense	47,711,700	13,875,600
Customer Lists [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	1,000,000	1,000,000
Finite-Lived Intangible Assets, Accumulated Amortization	(370,100)	(295,100)
Finite-Lived Intangible Assets, Future Amortization Expense	$ 629,900	704,900
Finite-Lived Intangible Assets, Useful Life	10 years
Manufacturing Technology [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	$ 3,900,000	3,900,000
Finite-Lived Intangible Assets, Accumulated Amortization	(1,443,400)	(1,150,900)
Finite-Lived Intangible Assets, Future Amortization Expense	$ 2,456,600	2,749,100
Finite-Lived Intangible Assets, Useful Life	10 years
Trade Names [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	$ 800,000	800,000
Finite-Lived Intangible Assets, Accumulated Amortization	(296,100)	(236,100)
Finite-Lived Intangible Assets, Future Amortization Expense	$ 503,900	563,900
Finite-Lived Intangible Assets, Useful Life	10 years
In Process R and D [Member]
Goodwill [Roll Forward]
Other Indefinite-lived Intangible Assets	$ 43,690,000	9,400,000
VSEL Patent Rights [Member]
Goodwill [Roll Forward]
Finite-Lived Intangible Assets, Gross	669,000	669,000
Finite-Lived Intangible Assets, Accumulated Amortization	(237,700)	(211,300)
Finite-Lived Intangible Assets, Future Amortization Expense	$ 431,300	$ 457,700
Finite-Lived Intangible Assets, Useful Life	19 years
NeoStem, Inc. [Member]
Goodwill [Roll Forward]
Goodwill	$ 11,117.8
Goodwill	25,209.3
NeoStem Oncology [Member]
Goodwill [Roll Forward]
Goodwill, Acquired During Period	$ 14,091.5

Goodwill and Other Intangible Assets Intangible Amortization Expense (Details) - USD ($)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 453,900	$ 453,900
Cost of revenue
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	237,600	292,500
Research and development
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	81,300	26,400
Selling, general and administrative
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 135,000	$ 135,000

Goodwill and Other Intangible Assets Goodwill (Details) - USD ($)	Sep. 30, 2014	Dec. 31, 2013
Goodwill [Abstract]
Future Amortization Expense, Year One	$ 151,300
Future Amortization Expense, Year Two	605,200
Future Amortization Expense, Year Three	605,200
Future Amortization Expense, Year Four	605,200
Future, Amortization Expense, Year Five	605,200
Thereafter	45,139,600
Finite-Lived Intangible Assets, Future Amortization Expense	$ 47,711,700	$ 13,875,600

Accrued Liabilities Accrued Liabilities (Details) - USD ($)	Sep. 30, 2014	Dec. 31, 2013
Accrued Liabilities [Abstract]
Salaries, employee benefits and related taxes	$ 1,435,600	$ 2,325,800
Professional fees	608,200	544,800
License fees	100,000	500,000
Other	674,800	647,400
Accrued Liabilities	$ 2,818,600	$ 4,018,000

Debt (Details) - USD ($)			9 Months Ended
Debt (Details) - USD ($)	Dec. 06, 2010	Oct. 31, 2007	Sep. 30, 2014	Sep. 26, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Notes Payable			$ 2,000,000		$ 900,000
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months			200,000
Mortgages payable			0	$ 20,000,000	3,023,609
Debt Instrument, Periodic Payment			10,000,000
Proceeds from Issuance of Debt			11,700,000
Debt Issuance Cost			(100,000)
Interest Expense, Long-term Debt			17,708
Mortgage Loans on Real Estate, Carrying Amount of Mortgages			3,100,000
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Two			2,400,000
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Three			5,700,000
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Four			5,700,000
Long-term Debt and Capital Lease Obligations, Maturities, Repayments of Principal in Year Five			5,500,000
Long-term Debt			$ 19,500,000
Impaired Long-Lived Assets Held and Used, Asset Name [Domain]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Interest			8.00%
Long-term Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum			8.50%
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Purchase of condominium units		$ 3,800,000
Debt Instrument, Periodic Payment, Interest			5.00%
Mortgage Loans on Real Estate, Carrying Amount of Mortgages			$ 2,400,000		2,500,000
Mortgage Loans on Real Estate, New Mortgage Loans		$ 3,100,000
NeoStem, Inc. [Member] \| Long-term Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Period of Loan			36 months
Debt Instrument, Payment Terms			30 months
PCT Allendale, LLC [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment			$ 20,766
PCT Allendale, LLC [Member] \| Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Periodic Payment, Interest	6.00%
Mortgage Loans on Real Estate, Carrying Amount of Mortgages			$ 705,962.96		$ 763,000
Mortgage Loans on Real Estate, New Mortgage Loans	$ 1,000,000
Debt Instrument, Period of Loan	124 months
Debt Instrument, Period of Fixed Interest Rate	64 months
Long-term Debt [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross				15,000,000
License Agreement Terms [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross				$ 5,000,000

Shareholders' Equity Reverse Stock Split (Details) - $ / shares	Sep. 30, 2014	Dec. 31, 2013	Jul. 26, 2013
Statement of Stockholders' Equity [Abstract]
Common Stock, Par Value	$ 0.001	$ 0.001	$ 0.001

Shareholders' Equity Equity Issuances (Details)	3 Months Ended	9 Months Ended
Shareholders' Equity Equity Issuances (Details)	Mar. 31, 2014 USD ($) shares	Sep. 30, 2014 USD ($) $ / shares shares	Sep. 30, 2013 USD ($)	Oct. 06, 2014 shares	May 08, 2014 shares	Dec. 31, 2013 shares	Sep. 28, 2011
Class of Stock [Line Items]
Common Stock, Shares Authorized		500,000,000				500,000,000
Common Stock, Shares, Issued		35,485,523			5,329,593	27,196,537
Net proceeds from issuance of common stock \| $		$ 11,275,109	$ 21,517,422
Stock Option Exercise		48,987
Proceeds from Stock Options Exercised \| $		$ 300,000
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Committment Value Under Purchase Agreement \| $	$ 20,000,000
Term Of Agreement In Months	24						24
Discount Applied To Weighted Average Price	5.00%
Proceeds from Issuance of Common Stock Gross \| $	$ 5,600,000
Stock Issued During Period, Shares, New Issues		900,000
Net proceeds from issuance of common stock \| $		$ 5,600,000
Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]
Common Stock, Shares, Issued	150,000
Purchase Commitment, Remaining Minimum Amount Committed \| $	$ 30,000,000
Stock Issued During Period, Shares, New Issues	800,000
Maximum [Member]
Class of Stock [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit \| $ / shares		$ 6.20
Minimum [Member]
Class of Stock [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit \| $ / shares		$ 5.20
Common Stock [Member] \| 2009 Equity Plan [Member] \| Stock Options [Member]
Class of Stock [Line Items]
Excess Stock, Shares Authorized				3,000,000
Common Stock, Shares Authorized				8,995,000

Shareholders' Equity Warrant Exercises (Details) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2014 USD ($) $ / shares shares
Warrant holder A [Member]
Stock Options and Warrants [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares	333,250
Proceeds from Issuance of Warrants \| $	$ 1.7
Minimum [Member]
Stock Options and Warrants [Line Items]
Investment Warrants, Exercise Price	$ 5.1
Maximum [Member]
Stock Options and Warrants [Line Items]
Investment Warrants, Exercise Price	$ 14.5

Shareholders' Equity Stock options and warrants (Details)	9 Months Ended		12 Months Ended
	Sep. 30, 2014 USD ($) $ / shares $ / warrant shares	Sep. 30, 2013 USD ($) shares	Dec. 31, 2013 USD ($) $ / shares $ / warrant shares
Stock Options and Warrants [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value \| $	$ 580,900		$ 1,658,100
Common Stock Warrants, Shares	3,555,956		4,898,266
Weighted Average Exercise Price, Warrants Outstanding \| $ / warrant	14.13		16.50
Weighted Average Remaining Contractual Term warrant outstanding	2 years 4 months 13 days		2 years 7 months 17 days
Aggregate Intrinsic Value, Warrants Outstanding \| $	$ 273,200		$ 1,811,000
Warrants Granted	2,722
Warrants Granted	0	20,407
Weighted Average Exercise Price, Warrants Granted \| $ / shares	$ 12.26
Warrants Exercised	(333,250)
Weighted Average Exercise Price, Warrants Exercised \| $ / shares	$ 5.16
Warrants Expired	(100,108)
Weighted Average Exercise Price, Warrants Expired \| $ / shares	$ 70.00
Warrants Canceled	(911,674)
Weighted Average Exercise Price, Warrants Canceled \| $ / shares	$ 23.97
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value \| $	$ 561,200
shares, vested and expected to vest	3,555,956
Weighted Average Exercise Price, Warrants vested & expected to vest \| $ / warrant	14.13
Aggregate Intrinsic Value, Warrants vested and expected to vest \| $	$ 273,200
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value \| $	$ 403,900
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	3,545,956
Weighted Average Exercise Price, Warrants Exercisable \| $ / warrant	14.15
weighted Average Remaining Contractual Term, warrants vested	2 years 4 months 13 days
Aggregate Intrinsic Value, Warrants vested \| $	$ 273,200
Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants \| $	$ 0	$ 70,500
US Equity Plan [Member]
Stock Options and Warrants [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	4,459,923		2,932,191
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 9.24		$ 11.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	7 years 6 months 22 days		6 years 9 months 22 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	2,102,525
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price \| $ / shares	$ 6.85
Stock Options Exercised	(48,987)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price \| $ / shares	$ 5.53
Stock Options Expired	(262,954)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price \| $ / shares	$ 6.54
Stock Options Forfeited	(262,852)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price \| $ / shares	$ 15.18
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	4,172,772
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price \| $ / shares	$ 9.38
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	7 years 5 months 9 days
Weighted Average Remaining Contractual Term, Warrants Vested and Expect to Vest	2 years 4 months 13 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	2,823,720
Weighted average estimated fair value of shares granted \| $ / shares	$ 10.36
Options, Vested, weighted Average Remaining Contractual Term	6 years 8 months 23 days
Minimum [Member]
Stock Options and Warrants [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit \| $ / shares	$ 5.20
Maximum [Member]
Stock Options and Warrants [Line Items]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit \| $ / shares	$ 6.20

Shareholders' Equity Restricted Stock (Details) - USD ($)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross	708,706	452,454
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 4,964,000	$ 2,967,700
weighted average estimated fair value of restricted stock	$ 7.00	$ 6.56

Shareholders' Equity Option Exercise (Details) $ in Millions	9 Months Ended
	Sep. 30, 2014 USD ($) shares
Shareholders’ Equity [Abstract]
Proceeds from Stock Options Exercised \| $	$ 0.3
Stock Option Exercise \| shares	48,987

Share-Based Compensation Share-Based Compensation (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 3,287,900	$ 2,127,600	$ 8,941,500	$ 5,412,500
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	6,266,700		$ 6,266,700
Expected weighted-average period in years of compensation cost to be recognized			4 years 11 months 9 days
Warrants
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 20,400		$ 20,400
Expected weighted-average period in years of compensation cost to be recognized			9 months 15 days
Total fair value of shares vested			$ 15,300	123,000
Weighted average estimated fair value of shares granted	$ 0.00		$ 0.00		$ 3.45
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average estimated fair value of shares granted	$ 4.67		$ 4.67		$ 4.30
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost	$ 327,400		$ 327,400
Expected weighted-average period in years of compensation cost to be recognized			3 months 22 days
Cost of revenue
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	55,900	88,800	$ 292,600	233,700
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	515,700	319,900	1,364,200	667,000
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense	$ 2,716,300	$ 1,718,900	7,284,700	4,511,800
Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total fair value of shares vested			$ 4,141,600	$ 2,470,000

Income Taxes Net Operating Loss Carry Forward (Details) - USD ($)	Sep. 30, 2014	Dec. 31, 2013
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards		$ 110,600,000
Deferred Tax Liabilities, Net, Noncurrent	$ 18,422,575	$ 4,379,226

Commitments and Contingencies (Details) - USD ($)	3 Months Ended		9 Months Ended
Commitments and Contingencies (Details) - USD ($)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Operating Leases, Future Minimum Payments Due [Abstract]
2013	$ 337,200		$ 337,200
2014	1,162,500		1,162,500
2015	999,900		999,900
2016	699,800		699,800
Thereafter	7,000		7,000
Total minimum lease payments	3,206,400		3,206,400
Operating Leases, Rent Expense	$ 400,000	$ 300,000	$ 900,000	$ 900,000